MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.000
-0.020
-1.96%
After Hours: 1.000 0 0.00% 16:38 10/28 EDT
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.010
LOW
0.9700
VOLUME
487.44K
TURNOVER
--
52 WEEK HIGH
1.970
52 WEEK LOW
0.4000
MARKET CAP
55.48M
P/E (TTM)
-1.8103
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Citius Pharmaceuticals Issues October 2020 Letter to Shareholders
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has issued an October 2020 Letter to Shareholders. The letter addresses recent updates on the Company's business and clinical developments and news for its pipeline of products.
PR Newswire · 1d ago
Citius Pharmaceutics Expects Mini-Lok Phase 3 Trial Will Continued As Planned Until It Is Fully Enrolled, Expect To Be In First Half Of 2021
-SEC Filing
SEC Filing · 2d ago
Citius Pharma 8-K Shows Letter To Shareholders
Dear Fellow Shareholders,   Citius Pharmaceuticals, Inc. (“Company”) has made considerable progress in 2020 with recent developments designed to contribute to increased value for our shareholders.
Benzinga · 2d ago
Citius Pharmaceuticals: Phase 3 Catalyst Countdown And Ready For Take Off
Citius Pharmaceuticals is nearing the completion of its Phase 3 trial with top-line data due Dec 2020 (or sooner).Mino-Lok fills an unmet medical need in the CRBSI space for Central Venous Catheters with potential annual US sales of $500M.The Chairman of the Board has extensive experience in creating strong brands and a history of selling successful products & companies.At $55M market capitalization, the Company is significantly undervalued.
Seekingalpha · 10/16 17:45
Citius Pharma in-licenses cell therapy for COVID-19 and other respiratory conditions
Novellus Therapeutics has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to a subsidiary of Citius Pharmaceuticals (CTXR), NoveCite, Inc.NoveCite will develop and commercialize Novellus's iMSCs to
Seekingalpha · 10/13 12:03
Novellus Therapeutics Reports It Has Licensed Its Induced Mesenchymal Stem Cells On Global Basis To Newly-Formed Subsidairy Of Citius Pharma, NoveCite; NoveCite To Develop, Commercialize For Acute Respiratory Conditions
Novellus Therapeutics ("Novellus"), an engineered cellular medicines company, announced today that it has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, Inc., a newly
Benzinga · 10/13 11:32
Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions
Novellus Therapeutics ("Novellus"), an engineered cellular medicines company, announced today that it has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, Inc., a newly formed subsidiary of Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products. NoveCite will develop and commercialize Novellus's iMSCs to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19. Novellus is a 25% equity holder in NoveCite. Novellus received a $5 million upfront payment, and is eligible to receive up to $51 million in development milestone payments, as well as low double-digit royalties.
PR Newswire · 10/13 11:30
Citius Pharma inks license pact with Novellus for stem cell therapy in respiratory distress
Citius Pharmaceuticals (CTXR) has exercised its previously announced option agreement, and announced an exclusive agreement with Novellus Therapeutics to license iPSC-derived mesenchymal stem cells (iMSCs).The company has created a new subsidiary,
Seekingalpha · 10/07 11:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTXR. Analyze the recent business situations of Citius Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTXR stock price target is 5.50 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 1.07M
% Owned: 1.93%
Shares Outstanding: 55.48M
TypeInstitutionsShares
Increased
3
96.05K
New
11
-1.25M
Decreased
1
16.47K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.66%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Executive Director/Secretary
Leonard Mazur
President/Chief Executive Officer/Director
Myron Holubiak
Chief Financial Officer
Jaime Bartushak
Independent Director
Suren Dutia
Independent Director
Eugene Holuka
Independent Director
William Kane
Independent Director
Howard Safir
Independent Director
Carol Webb
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CTXR
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is focused on developing and commercializing care products with a focus on anti-infective products in adjunct cancer care and prescription products. It has three product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok product is designed to salvage the central venous catheters CVC, obviating the need to remove and replace the catheter. Mino-Wrap is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the steroid, halobetasol, with lidocaine.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Citius Pharmaceuticals Inc stock information, including NASDAQ:CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.